快速訂購

HER2 Targeted Therapy

Targeted Therapy
What is Targeted Therapy
Targeted Therapy: Targets
Targeted Therapy for Cancer
- Targeted Therapy for Kidney Cancer
- Targeted Therapy for Liver Cancer
- Colorectal Cancer Targeted Therapy
- What is Targeted Therapy for Cancer
- Targeted Therapy for Leukemia
- Targeted Therapy for Pancreatic Cancer
- Prostate Cancer Targeted Therapy
- Targeted Therapy for Ovarian Cancer
- Melanoma Targeted Therapy
- Targeted Therapy for Lung Cancer
- Targeted Therapy for Breast Cancer
EGFR Targeted Therapy
- EGFR Targeted Therapy for Breast Cancer
- EGFR Targeted Therapy for Colorectal Cancer
- EGFR Targeted Therapy for Head and Neck Cancer
- EGFR Targeted Therapy for Non-Small-Cell Lung Cancer
- EGFR Targeted Therapy for Ovarian Cancer
- EGFR Targeted Therapy for Pancreatic Cancer
HER2 Targeted Therapy
- HER2 Targeted Therapy for Breast Cancer
- HER2 Targeted Therapy for Colorectal Cancer
- Her2 targeted therapy for Ovarian cancer
VEGF Targeted Therapy
- VEGF Targeted Therapy for Breast Cancer
- VEGF Targeted Therapy for Lung Cancer
- VEGF Targeted Therapy for Prostate Cancer
- VEGF Targeted Therapy for Colorectal Cancer
BRAF Targeted Therapy
- BRAF Targeted Therapy for Melanoma
- BRAF Targeted Therapy for Lung Cancer
ALK Targeted Therapy
- ALK Targeted Therapy for Lung Cancer
- ALK Targeted Therapy for Anaplastic Large Cell Lymphoma
Immune Checkpoint Targeted Therapy
Targeted Therapy Drugs
- Targeted Therapy Drugs: Elotuzumab
- Targeted Therapy Drugs: Necitumumab
- Targeted Therapy Drugs: Daratumumab
- Targeted Therapy Drugs: Ramucirumab
- Targeted Therapy Drugs: Trastuzumab
- Targeted Therapy Drugs: Vemurafenib
- Targeted Therapy Drugs: Crizotinib
- The Differences between Chemotherapy and Targeted Therapy
Side Effects of Targeted Therapy
Oral Targeted Therapy
Targeted Therapy Resistance
How does Targeted Therapy Work
Immunotherapy
Cancer Immunotherapy
Immune checkpoint

HER2 Targeted Therapy: Introduction

HER2 belongs to a family of receptor tyrosine kinases (RTKs) that includes EGFR/ERBB1, HER2/ERBB2/NEU, HER3/ERBB3, and HER4/ERBB4. The gene for HER2 is located on chromosome 17 and has been found to be amplified with an increased copy number in several cancers. Amplification of HER2 has been found to promote tumorigenesis and to be involved in the pathogenesis of several human cancers.
To date, no ligand has been identified for HER2. However, HER2 appears to be the preferential dimerization partner for all members of the ERBB family. The binding of ligand followed by HER2 hetero-dimerization results in activation of HER2 tyrosine kinase activity. Activated HER2 then phosphorylates its substrates, leading to activation of multiple downstream pathways within the cell, including the PI3K-AKT-mTOR pathway, which is involved in cell survival, and the RAS-RAF-MEK-ERK pathway, which is involved in cell proliferation.

HER2 Targeted Therapy: Breast Cancer

Amplification of the HER2 gene and/or overexpression at the messenger RNA or protein level occurs in about 20% of patients with early stage breast cancer. Before the advent of HER2-directed therapies, this increased level of HER2 was associated with high recurrence rates and increased mortality in patients. The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing now.

HER2 Targeted Therapy: Colorectal Cancer

Although chemotherapy has shown to be an efficient strategy for adjuvant therapy in colorectal cancer, it is still not capable of preventing recurrence in all patients. Therefore there is numerous ongoing research for alternative compounds to be used as adjuvant therapy. Monoclonal antibodies and other biologicals, targeting tumor-associated proteins and blocking essential processes of the tumor, are extensively studied. A crucial step in this process is the identification of tumor specific proteins that can be targeted by these compounds. One of these targets is HER2, which is primarily associated with breast cancer.

HER2 Targeted Therapy: Ovarian Cancer

Because symptoms are usually absent, 70 to 80% of patients with ovarian cancer will have advanced disease at the time of diagnosis. Despite an initial good response to first-line combination chemotherapy (taxane/platinum), relapses are frequent because of acquired chemoresistance. The use of new targeted therapies that are potentially effective in a subset of patients may be of great value.

請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”